Approvals for Pfizer's bosutinib, axitinib

Pfizer Inc. (NYSE:PFE) announced approvals Tuesday for two cancer drugs: Bosulif bosutinib in the U.S. and Inlyta axitinib in Europe. FDA approved Bosulif to treat chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in patients who are resistant, or intolerant to prior therapy. The product is a dual inhibitor of BCR-ABL and Src kinase. ...